AlphaQuest LLC Acquires Shares of 5,120 Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• AlphaQuest LLC has acquired **5,120 shares** of Zimmer Biomet Holdings, valued at approximately **$579,000**, as per its latest Form 13F filing.
• Zimmer Biomet reported **$2.07 EPS** for the last quarter, exceeding analysts' expectations of **$1.98**, with revenues reaching **$2.08 billion**.
• Recent analyst reports have seen **price targets** on Zimmer Biomet adjusted, with JMP Securities lowering theirs from **$140.00 to $125.00** while Royal Bank of Canada increased theirs to **$115.00**.

AlphaQuest LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,120 shares of the medical equipment provider's stock, valued at approximately $579,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at $269,000. Keybank National Association OH boosted its stake in Zimmer Biomet by 61.2% in the first quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider's stock worth $1,620,000 after purchasing an additional 5,434 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Zimmer Biomet by 26.4% in the first quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider's stock worth $35,800,000 after purchasing an additional 66,114 shares in the last quarter. Kingswood Wealth Advisors LLC raised its holdings in shares of Zimmer Biomet by 20.0% in the first quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock valued at $295,000 after buying an additional 435 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of Zimmer Biomet by 10.8% in the fourth quarter. Stifel Financial Corp now owns 96,032 shares of the medical equipment provider's stock valued at $10,144,000 after buying an additional 9,341 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $107.3520 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market cap of $21.27 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.12 and a beta of 0.68. The stock has a 50-day moving average of $95.82 and a 200-day moving average of $99.28. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.Zimmer Biomet's revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were issued a $0.24 dividend. The ex-dividend date was Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. JMP Securities cut their price target on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. UBS Group lifted their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Morgan Stanley cut their price target on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Nine investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $111.44.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the sale, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.